NEW YORK (GenomeWeb) – Inform Genomics today announced it has raised $2.6 million in a private placement of preferred stock. 

The firm did not say who the participants in the financing were. It said that the proceeds will go toward advancing its lead programs to support cancer care, including OnPart and HSCT/Mucositis; the development of a proprietary analytic platform; and for general corporate uses, including patent filings and working capital. 

OnPart and MSCT/Mucositis are platforms for predicting a patient's risk for developing common chemotherapy-related side effects. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.